ECSP11011112A - Combinación antitumoral que asocia a ve8062 y docetaxel - Google Patents
Combinación antitumoral que asocia a ve8062 y docetaxelInfo
- Publication number
- ECSP11011112A ECSP11011112A EC2011011112A ECSP11011112A ECSP11011112A EC SP11011112 A ECSP11011112 A EC SP11011112A EC 2011011112 A EC2011011112 A EC 2011011112A EC SP11011112 A ECSP11011112 A EC SP11011112A EC SP11011112 A ECSP11011112 A EC SP11011112A
- Authority
- EC
- Ecuador
- Prior art keywords
- docetaxel
- combination associating
- antitumoral combination
- antitumoral
- associating
- Prior art date
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title abstract 3
- 229960003668 docetaxel Drugs 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 abstract 2
- 229950003600 ombrabulin Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención se refiere a una combinación antitumoral y secuencial de AVE8062 o una de sus sales y docetaxel, caracterizada por que AVE8062 se administra a un paciente a una dosis de 10 a 50 mg/m2 y a continuación, un día diferente de la semana, preferiblemente después de un intervalo de 24 horas, se administra el docetaxel a una dosis comprendida entre 50 y 120 mg/m2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0806979A FR2939665B1 (fr) | 2008-12-12 | 2008-12-12 | Combinaison antitumorale associant l'ave8062a et le docetaxel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011112A true ECSP11011112A (es) | 2011-07-29 |
Family
ID=40790630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011112A ECSP11011112A (es) | 2008-12-12 | 2011-06-07 | Combinación antitumoral que asocia a ve8062 y docetaxel |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20120004294A1 (es) |
| EP (1) | EP2376076A1 (es) |
| JP (1) | JP2012511554A (es) |
| KR (1) | KR20110104932A (es) |
| CN (1) | CN102245175A (es) |
| AR (1) | AR074599A1 (es) |
| AU (1) | AU2009326220A1 (es) |
| BR (1) | BRPI0923349A2 (es) |
| CA (1) | CA2746475A1 (es) |
| CL (1) | CL2011001316A1 (es) |
| CO (1) | CO6390037A2 (es) |
| CR (1) | CR20110319A (es) |
| EA (1) | EA201170803A1 (es) |
| EC (1) | ECSP11011112A (es) |
| FR (1) | FR2939665B1 (es) |
| IL (1) | IL213458A0 (es) |
| MA (1) | MA32955B1 (es) |
| MX (1) | MX2011006253A (es) |
| NI (1) | NI201100114A (es) |
| PA (1) | PA8853301A1 (es) |
| PE (1) | PE20120125A1 (es) |
| SG (1) | SG172071A1 (es) |
| TN (1) | TN2011000268A1 (es) |
| TW (1) | TW201032798A (es) |
| UY (1) | UY32318A (es) |
| WO (1) | WO2010067027A1 (es) |
| ZA (1) | ZA201104358B (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601676B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
| FR2601675B1 (fr) | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| US20050209310A1 (en) | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| WO2002056692A1 (en) | 2000-12-22 | 2002-07-25 | Bristol-Myers Squibb Company | Methods for modulating tumor growth and metastasis |
| US20020183266A1 (en) * | 2001-03-15 | 2002-12-05 | Aventis Pharma, S.A. | Combination comprising combretastatin and anticancer agents |
| FR2838437B1 (fr) | 2002-04-11 | 2004-06-04 | Aventis Pharma Sa | Procedes de preparation de combretastatines |
-
2008
- 2008-12-12 FR FR0806979A patent/FR2939665B1/fr not_active Expired - Fee Related
-
2009
- 2009-12-10 PE PE2011001197A patent/PE20120125A1/es not_active Application Discontinuation
- 2009-12-10 JP JP2011540175A patent/JP2012511554A/ja active Pending
- 2009-12-10 CN CN2009801497729A patent/CN102245175A/zh active Pending
- 2009-12-10 MA MA34002A patent/MA32955B1/fr unknown
- 2009-12-10 CA CA2746475A patent/CA2746475A1/fr not_active Abandoned
- 2009-12-10 WO PCT/FR2009/052475 patent/WO2010067027A1/fr not_active Ceased
- 2009-12-10 TW TW098142340A patent/TW201032798A/zh unknown
- 2009-12-10 BR BRPI0923349-0A patent/BRPI0923349A2/pt not_active IP Right Cessation
- 2009-12-10 MX MX2011006253A patent/MX2011006253A/es not_active Application Discontinuation
- 2009-12-10 EP EP09802160A patent/EP2376076A1/fr not_active Withdrawn
- 2009-12-10 EA EA201170803A patent/EA201170803A1/ru unknown
- 2009-12-10 AU AU2009326220A patent/AU2009326220A1/en not_active Abandoned
- 2009-12-10 SG SG2011042348A patent/SG172071A1/en unknown
- 2009-12-10 KR KR1020117013250A patent/KR20110104932A/ko not_active Withdrawn
- 2009-12-11 UY UY0001032318A patent/UY32318A/es not_active Application Discontinuation
- 2009-12-11 AR ARP090104814A patent/AR074599A1/es not_active Application Discontinuation
- 2009-12-11 PA PA20098853301A patent/PA8853301A1/es unknown
-
2011
- 2011-05-24 TN TN2011000268A patent/TN2011000268A1/fr unknown
- 2011-06-02 CL CL2011001316A patent/CL2011001316A1/es unknown
- 2011-06-06 US US13/153,975 patent/US20120004294A1/en not_active Abandoned
- 2011-06-07 EC EC2011011112A patent/ECSP11011112A/es unknown
- 2011-06-08 NI NI201100114A patent/NI201100114A/es unknown
- 2011-06-08 CR CR20110319A patent/CR20110319A/es unknown
- 2011-06-09 IL IL213458A patent/IL213458A0/en unknown
- 2011-06-10 CO CO11072133A patent/CO6390037A2/es not_active Application Discontinuation
- 2011-06-10 ZA ZA2011/04358A patent/ZA201104358B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2011001316A1 (es) | 2011-10-28 |
| FR2939665B1 (fr) | 2011-10-07 |
| KR20110104932A (ko) | 2011-09-23 |
| PA8853301A1 (es) | 2010-07-27 |
| TN2011000268A1 (fr) | 2012-12-17 |
| JP2012511554A (ja) | 2012-05-24 |
| TW201032798A (en) | 2010-09-16 |
| EP2376076A1 (fr) | 2011-10-19 |
| US20120004294A1 (en) | 2012-01-05 |
| SG172071A1 (en) | 2011-07-28 |
| CR20110319A (es) | 2011-09-20 |
| WO2010067027A1 (fr) | 2010-06-17 |
| IL213458A0 (en) | 2011-07-31 |
| CA2746475A1 (fr) | 2010-06-17 |
| MA32955B1 (fr) | 2012-01-02 |
| CN102245175A (zh) | 2011-11-16 |
| UY32318A (es) | 2010-07-30 |
| AU2009326220A1 (en) | 2011-07-07 |
| AR074599A1 (es) | 2011-01-26 |
| ZA201104358B (en) | 2012-09-26 |
| CO6390037A2 (es) | 2012-02-29 |
| MX2011006253A (es) | 2011-11-04 |
| EA201170803A1 (ru) | 2011-12-30 |
| PE20120125A1 (es) | 2012-02-23 |
| FR2939665A1 (fr) | 2010-06-18 |
| BRPI0923349A2 (pt) | 2015-07-21 |
| NI201100114A (es) | 2011-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| CR20110424A (es) | Derivados de aminotetralina, composiciones farmacéuticas que los contienen, y sus usos en terapia | |
| PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
| AR065392A1 (es) | Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio | |
| CL2008000896A1 (es) | Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal. | |
| EA201290833A1 (ru) | Применение амисульприда в качестве противорвотного средства | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2013011336A (es) | Composiciones farmaceuticas intranasales de benzodiazepina. | |
| AR086422A1 (es) | Metodo para el tratamiento de tumores solidos avanzados, volasertib | |
| PE20120791A1 (es) | Composiciones y metodos para terapia prolongada con aminopiridinas | |
| AR089509A1 (es) | Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso | |
| AR072516A1 (es) | Metodos, sistemas y dispositivos para la administracion de dioxido de cloro a un tejido | |
| EA201171497A1 (ru) | Снижение флуктуаций опиоидов в крови | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| EA201071209A1 (ru) | Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови | |
| TR200900879A2 (tr) | Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler | |
| PE20130147A1 (es) | Combinacion farmaceutica de teobromina y un agente antitusivo no opioide | |
| CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. | |
| DOP2010000327A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona | |
| CY1118925T1 (el) | Θεραπεια ασθενειας με αναστολεις πρωτεασωματος | |
| UY32507A (es) | Una dosis de ave5026 para el tratamiento de trombormbolismo venoso en pacientes con deterioro renal severo | |
| PE20061051A1 (es) | Composicion farmaceutica que comprende mirtazapina s | |
| GT200800208A (es) | Composición farmacèutica que comprende la combinación de una sal de ketorolaco y vitaminas del complejo b para el tratamiento de la neuralgia. | |
| CO6390037A2 (es) | Combinación antitumoral que asocia ave8062 y docetaxel |